GlpBio

HC 067047

目录号: GC12260纯度: >99.00%
HC 067047是TRPV4通道的选择性拮抗剂，对人、大鼠和小鼠TRPV4的IC50分别为48±6nM, 133±25nM和17±3nM。
HC 067047
Cas No.: 883031-03-6
规格价格库存数量操作
5mg¥462.00现货
1
10mg¥770.00现货
1
25mg¥1,586.00现货
1
50mg¥2,529.00现货
1
100mg¥3,693.00现货
1
10mM (in 1mL DMSO)¥480.00现货
1
电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

HC 067047 is a selective antagonist of the TRPV4 channel. HC 067047 exhibits IC50 values of 48±6nM, 133±25nM and 17±3nM against human, rat, and mouse TRPV4 channels, respectively[1].

In vitro, HC 067047 (1μM; 5min) reduces mechanoactivated currents in Schwann cells[2]. HC 067047 (1μM; 30min) reversed the hypoxia/reoxygenation (H/R)-induced elevation of intracellular Ca2+ concentration ([Ca²⁺]ᵢ) and cell injury[3].

In vivo, HC 067047 (1mg/kg; 5 weeks; s.c.) prevented the development of mechanical, but not thermal cold allodynia in diabetic mice[4]. Treatment with the selective TRPV4 antagonist HC 067047 (5, 10 and 20mg/kg; i.p.) significantly attenuated myocardial ischemia/reperfusion (I/R) injury[5]. HC 067047 (10mg/kg; i.p.) exerts protective effects against RB-induced lung injury[6].

References:
[1] Everaerts W, Zhen X, Ghosh D, Vriens J, Gevaert T, Gilbert JP, Hayward NJ, McNamara CR, Xue F, Moran MM, Strassmaier T, Uykal E, Owsianik G, Vennekens R, De Ridder D, Nilius B, Fanger CM, Voets T. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084-9.
[2] Mulpuri Y, Tu NH, Inoue K, Harden G, Nicholson SJ, Seenauth A, Huang Y, Escobar KG, Moayedi Y, Bunnett NW, Albertson DG, Schmidt BL. TRPV4 activation in Schwann cells mediates mechanically induced pain of oral cancer. Front Pain Res (Lausanne). 2025 Mar 12;6:1532885.
[3] Wu QF, Qian C, Zhao N, Dong Q, Li J, Wang BB, Chen L, Yu L, Han B, Du YM, Liao YH. Activation of transient receptor potential vanilloid 4 involves in hypoxia/reoxygenation injury in cardiomyocytes. Cell Death Dis. 2017 May 25;8(5):e2828.
[4] Dias FC, Alves VS, Matias DO, Figueiredo CP, Miranda ALP, Passos GF, Costa R. The selective TRPV4 channel antagonist HC-067047 attenuates mechanical allodynia in diabetic mice. Eur J Pharmacol. 2019 Aug 5;856:172408.
[5] Dong Q, Li J, Wu QF, Zhao N, Qian C, Ding D, Wang BB, Chen L, Guo KF, Fu D, Han B, Liao YH, Du YM. Blockage of transient receptor potential vanilloid 4 alleviates myocardial ischemia/reperfusion injury in mice. Sci Rep. 2017 Feb 16;7:42678.
[6] Toumpanakis D, Chatzianastasiou A, Vassilakopoulou V, Mizi E, Dettoraki M, Perlikos F, Giatra G, Mikos N, Theocharis S, Vassilakopoulos T. TRPV4 Inhibition Exerts Protective Effects Against Resistive Breathing Induced Lung Injury. Int J Chron Obstruct Pulmon Dis. 2022 Feb 15;17:343-353.

HC 067047是TRPV4通道的选择性拮抗剂，对人、大鼠和小鼠TRPV4的IC50分别为48±6nM, 133±25nM和17±3nM[1]。

在体外，HC 067047 (1μM; 5min)可抑制施万细胞中的机械激活电流[2]；HC 067047 (1μM; 30min)能逆转缺氧/复氧(H/R)引起的细胞内钙离子浓度([Ca²⁺]ᵢ)升高及细胞损伤[3]。

在体内，HC 067047 (1mg/kg; 5周; 皮下注射)可预防糖尿病小鼠机械性痛觉异常的发生，但对冷痛觉异常无效[4]；选择性TRPV4拮抗剂 HC 067047 (5, 10 and 20mg/kg; 腹腔注射)显著减轻心肌缺血/再灌注(I/R)损伤[5]。HC 067047 (10mg/kg; 腹腔注射)对辐射所致肺损伤亦具有保护作用[6]。

实验参考方法 Experimental Reference Method

Cell experiment [1]:

Cell lines

NRVM and H9C2 cells

Preparation Method

NRVM and H9C2 cells, pretreated with 1μM HC 067047 for 30min, were loaded with 2μM Fluo-4/AM for 30min and then washed three times with HEPES buffer. Cells in 96-well plates were excited at 488nm and fluorescence emissions at 525nm were recorded using the Enspire Multimode Plate Reader.

Reaction Conditions

1μM; 30min

Applications

HC 067047 reversed the hypoxia/reoxygenation (H/R)-induced elevation of intracellular Ca2+ concentration ([Ca2+]ᵢ) and cell injury.
Animal experiment [2]:

Animal models

Male Swiss mice (5-10 weeks)

Preparation Method

In order to assess the effect of the selective TRPV4 channel antagonist HC 067047 on the development of mechanical and cold allodynia, the drug was subcutaneously injected once a day, at the dose of 1mg/kg, between 2 and 6 weeks after diabetes induction. Control animals received vehicle (1% DMSO and 0.25% Tween 80 in saline solution). Mechanical and thermal cold allodynia were assessed in the sixth week of the experimental protocol.
To assess the therapeutic effect of HC 067047 on established mechanical and thermal cold allodynia, 6 weeks after diabetes induction the drug was given to both control and diabetic mice during 6 consecutive days (days 0-5). The drug was administered once a day by subcutaneous (s.c.) injections at the dose of 10mg/kg. Control animals received vehicle (8% DMSO and 2% Tween 80 in saline solution). Mechanical allodynia was assessed between 1 and 24h after a single injection of the drug on day 0, and 24h after each treatment on the remaining days (repeated treatment; days 2-6). Thermal cold allodynia was evaluated 2 and 24h after a single injection and 24h after each treatment on the remaining days.

Dosage form

1mg/kg; 5 weeks; s.c.

Applications

HC 067047 prevented the development of mechanical, but not thermal cold allodynia in diabetic mice.

References:
[1] Wu QF, Qian C, Zhao N, Dong Q, Li J, Wang BB, Chen L, Yu L, Han B, Du YM, Liao YH. Activation of transient receptor potential vanilloid 4 involves in hypoxia/reoxygenation injury in cardiomyocytes. Cell Death Dis. 2017 May 25;8(5):e2828.
[2] Dias FC, Alves VS, Matias DO, Figueiredo CP, Miranda ALP, Passos GF, Costa R. The selective TRPV4 channel antagonist HC-067047 attenuates mechanical allodynia in diabetic mice. Eur J Pharmacol. 2019 Aug 5;856:172408.

产品文档 Product Documents

Purity:>99.00%

化学性质Chemical Properties

CAS 号
883031-03-6
化学名
2-methyl-1-(3-morpholinopropyl)-5-phenyl-N-(3-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide
SMILES
FC(F)(C1=CC(NC(C2=C(C)N(C(C3=CC=CC=C3)=C2)CCCN4CCOCC4)=O)=CC=C1)F
分子式
C26H28F3N3O2
分子量
471.51 g/mol
溶解性
≥ 47.2mg/mL in DMSO
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol